Floatz logo

Durvalumab

Soft Tissue Sarcoma

Institut Bergoniémonoclonal_antibodyPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Inno-206
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3BB
Cyclophosphamide
Medigene AG
Phase 2BB
Tislelizumab
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BB
ETOPOSIDE
Masonic Cancer Center, University of Minnesota
Phase 2B
Docetaxel
Washington University School of Medicine
Phase 2B

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →